Arcutis Biotherapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Arcutis Biotherapeutics Debt-to-Equity Ratio Growth & History (ARQT)
Arcutis Biotherapeutics's debt-to-equity ratio was 0.60 for fiscal 2025.
View full Arcutis Biotherapeutics company overviewArcutis Biotherapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.60 | −0.10 | −13.90% |
| 2024 | 2024-12-31 | 0.70 | −1.62 | −69.77% |
| 2023 | 2023-12-31 | 2.32 | 1.36 | +140.30% |
| 2022 | 2022-12-31 | 0.97 | 0.71 | +270.93% |
| 2021 | 2021-12-31 | 0.26 | 0.24 | +1320.38% |
| 2020 | 2020-12-31 | 0.02 | — | — |
Arcutis Biotherapeutics quarterly debt-to-equity ratio
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.52 | −0.28 | −34.72% |
| Q1 2026 | 2026-03-31 | 0.60 | −0.17 | −22.15% |
| Q4 2025 | 2025-12-31 | 0.60 | −0.10 | −13.90% |
| Q3 2025 | 2025-09-30 | 0.72 | −0.61 | −45.84% |
| Q2 2025 | 2025-06-30 | 0.79 | −0.32 | −28.80% |
| Q1 2025 | 2025-03-31 | 0.78 | −0.14 | −15.49% |
| Q4 2024 | 2024-12-31 | 0.70 | −1.62 | −69.77% |
| Q3 2024 | 2024-09-30 | 1.33 | −3.06 | −69.72% |
| Q2 2024 | 2024-06-30 | 1.11 | −1.42 | −56.11% |
| Q1 2024 | 2024-03-31 | 0.92 | −0.54 | −36.85% |
| Q4 2023 | 2023-12-31 | 2.32 | 1.36 | +140.30% |
| Q3 2023 | 2023-09-30 | 4.39 | 3.64 | +489.35% |
| Q2 2023 | 2023-06-30 | 2.54 | 2.14 | +534.01% |
| Q1 2023 | 2023-03-31 | 1.46 | 1.15 | +374.38% |
| Q4 2022 | 2022-12-31 | 0.97 | 0.71 | +270.93% |
| Q3 2022 | 2022-09-30 | 0.74 | 0.73 | +5069.50% |
| Q2 2022 | 2022-06-30 | 0.40 | 0.39 | +3127.55% |
| Q1 2022 | 2022-03-31 | 0.31 | 0.30 | +2640.07% |
| Q4 2021 | 2021-12-31 | 0.26 | 0.24 | +1320.38% |
| Q3 2021 | 2021-09-30 | 0.01 | −0.01 | −32.73% |
| Q2 2021 | 2021-06-30 | 0.01 | −0.01 | −29.82% |
| Q1 2021 | 2021-03-31 | 0.01 | 0.01 | +925.94% |
| Q4 2020 | 2020-12-31 | 0.02 | — | — |
| Q3 2020 | 2020-09-30 | 0.02 | — | — |
| Q2 2020 | 2020-06-30 | 0.02 | — | — |
| Q1 2020 | 2020-03-31 | 0.00 | — | — |
Arcutis Biotherapeutics debt-to-equity ratio trends
Over the last five fiscal years, Arcutis Biotherapeutics's debt-to-equity ratio increased from 0.02 to 0.60, a change of 0.59. The latest reported quarter, Q2 2026, shows 0.52.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcutis Biotherapeutics source filings ↗